TCL Archive Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable January 31, 2003
TCL Archive Elderly and Younger Patients Have Similar Outcomes Following Radioembolization July 26, 2013
TCL Archive Massive New Radiation Research program Costing From $300-$400 Million Over 10 Years Suggested February 11, 1977